SLC5A2 and metabolic dysfunction-associated steatotic liver disease: These SGLT2 inhibitors can not only effectively reduce glucose oxidation and oxidative stress, but also accelerate lipolysis and effective free fatty acid oxidation, therapy resulting in a marked improvement in NAFLD [24].